Search
Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalIn April 2018, the U.S. … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].
Fenpropidin
go.drugbank.com/drugs/DB12728ApprovedWithdrawnFenpropidin has been investigated for the treatment of Hernia.
Categories: Compounds used in a research, industrial, or household settingVevorisertib
go.drugbank.com/drugs/DB21481Investigational(MK-4440-001)). … Vevorisertib is under investigation in clinical trial NCT02761694 (Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations
Iodipamide
go.drugbank.com/drugs/DB04711ApprovedWithdrawnIodipamide is a water-soluble radiographic contrast media for cholecystography and intravenous cholangiography.
Categories: Compounds used in a research, industrial, or household settingLys-63-specific deubiquitinase BRCC36
go.drugbank.com/bio_entities/BE0009071TargetHumansMediates the specific 'Lys-63'-specific deubiquitination associated with the COP9 signalosome complex (CSN), via the interaction of the BRISC complex with the CSN complex (PubMed:19214193). … Component of the BRCA1-A complex, a complex that specifically recognizes 'Lys-63'-linked ubiquitinated histones H2A and H2AX at DNA lesions sites, leading to target the BRCA1-BARD1 heterodimer to sites
Synonyms: BRCA1-A complex subunit BRCC36, BRISC complex subunit BRCC36Choline C 11
go.drugbank.com/drugs/DB09277Approved[A32041] It was developed by MCPRF and FDA first approved in September 2012.
Vayarin
go.drugbank.com/drugs/DB09328ApprovedVayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503]. … Vayarin is currently available only by prescription in the USA [L1502]. This drug has also been used for management of hypertriglyceridemia [L1503].
Crinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigational[A264818] Crinecerfont was approved by the FDA in December 2024 as an adjunct to glucocorticoid replacement in patients with CAH.[L51973,L51993] … [A264818] The majority of the poor health outcomes in patients with CAH result from the inability to precisely titrate glucocorticoid dosages to both adequately replace the deficiency and sufficiently
Trovafloxacin
go.drugbank.com/drugs/DB00685ApprovedWithdrawnIt exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. … It was shown to be more effective against Gram-positive bacteria than Gram-negative bacteria when compared to previous fluoroquinolones.
Hydroflumethiazide
go.drugbank.com/drugs/DB00774ApprovedWithdrawn(From Martindale, The Extra Pharmacopoeia, 30th ed, p822)